Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p3
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 3/66)
Character Range: 7394–10200

60  5     30

[16] Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)
omit:
Atorvastatin  Tablet 80 mg (as calcium)  Oral  Blooms the Chemist Atorvastatin  IB  MP NP             30  5     30
Atorvastatin  Tablet 80 mg (as calcium)  Oral  Blooms the Chemist Atorvastatin  IB  MP NP     P14238  60  5     30

[17] Schedule 1, Part 1, entries for Atropine in the form Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL
omit from the column headed "Brand" (all instances): Atropine Injection (Pfizer) substitute (all instances): Atropine Injection (Bridgewest)
[18] Schedule 1, Part 1, entry for Auranofin in each of the forms: Capsule 3 mg; and Tablet 3 mg
insert in the column headed "Circumstances": C15956
[19] Schedule 1, Part 1, entry for Avelumab
(a) omit from the column headed "Circumstances": C8947 C10023
(b) insert in numerical order in the column headed "Circumstances": C16053 C16085
[20] Schedule 1, Part 1, entries Azacitidine in each of the forms: Tablet 200 mg; and Tablet 300 mg
omit from the column headed "Responsible Person" (all instances): CJ  substitute (all instances): BQ
[21] Schedule 1, Part 1, fourth entry for Bimatoprost with timolol
omit from the column headed "Listed drug": Bimatoprost with timolol`` substitute: Bimatoprost with timolol
[22] Schedule 1, Part 1, entry for Bosentan in the form Tablet 62.5 mg (as monohydrate)
omit:
Bosentan  Tablet 62.5 mg (as monohydrate)  Oral  BOSLEER  RW  MP  See Note 3  See Note 3  See Note 3  See Note 3     60     D(100)

[23] Schedule 1, Part 1, entry for Bosentan in the form Tablet 125 mg (as monohydrate)
omit:
Bosentan  Tablet 125 mg (as monohydrate)  Oral  BOSLEER  RW  MP  See Note 3  See Note 3  See Note 3  See Note 3     60     D(100)

[24] Schedule 1, Part 1, entry for Buprenorphine in each of the forms: Injection (modified release) 8 mg in 0.16 mL pre-filled syringe; Injection (modified release) 16 mg in 0.32 mL pre-filled syringe; Injection (modified release) 24 mg in 0.48 mL pre-filled syringe; and Injection (modified release) 32 mg in 0.64 mL pre-filled syringe
omit from the column headed "Circumstances": C15385 substitute: C16051

[25] Schedule 1, Part 1, entry for Buprenorphine in each of the forms: Injection (modified release) 64 mg in 0.18 mL pre-filled syringe; and Injection (modified release) 96 mg in 0.27 mL pre-filled syringe
omit from the column headed "Circumstances": C15356 substitute: C16015
[26] Schedule 1, Part 1, entry for Buprenorphine in the form Injection (modified release) 100 mg in 0.5 mL pre-filled syringe
omit from the column headed "Circumstances": C15439 substitute: C16050
[27] Schedule 1, Part 1, entry for Buprenorphine in each of the forms: Injection (modified release) 128 mg in 0.36 mL pre-filled syringe; and Injection